Y.S.P. Industries


Y.S.P. Industries
Concise Prescribing Info
Varicella-zoster viral infections. Skin & mucous membrane infections due to herpes simplex virus. Prophylaxis of herpes simplex infection in immunocompromised patients including those w/ bone marrow transplant & leukaemia. Suppression of recurrent herpes simplex virus infection.
Dosage/Direction for Use
Adult Herpes simplex infection 200 mg (400 mg in the immunocompromised patient) 5 times daily for 5 days. Prevention of recurrent herpes simplex infection 200 mg qds or 400 mg bd, reduced to 200 mg bd-tds when indicated. Periodically interrupt therapy at 6-12 mth to observe possible changes in nature of disease. Prophylaxis of herpes simplex infection in immunocompromised patient 200 mg qds at 6-hr intervals. Severely immunocompromised patient Dose may be doubled to 400 mg. Varicella & herpes zoster infection 800 mg 5 times daily for 7 days. Paed Herpes simplex infection & prophylaxis of herpes simplex infection in immunocompromised Childn ≥2 yr Adult dose; <2 yr ½ adult dose. Varicella infection Childn >6 yr 800 mg qds; 2-6 yr 400 mg qds; <2 yr 200 mg qds. Dosing may be calculated as 20 mg/kg (max 800 mg) qds. Continue treatment for 5 days.
May be taken with or without food: May be taken w/ meals to reduce GI discomfort.
Special Precautions
Renal impairment. Pregnancy & lactation. Elderly.
Adverse Reactions
Rash, nausea, vomiting, abdominal pain. Occasionally, dizziness & somnolence. Increased bilirubin, liver enzymes, BUN & creatinine. Decreased haematological indices.
Drug Interactions
MIMS Class
ATC Classification
J05AB01 - aciclovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Virless tab 200 mg
5 × 10's
Virless tab 800 mg
5 × 5's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in